Executive Team

Miles Harrison is a healthcare and aesthetics executive with a proven record of scaling global businesses, driving innovation, and creating shareholder value.

He currently serves on the Board of Castle Biosciences (NASDAQ: CSTL), and sits on the Compensation Committee and Nominating and Governance Committee, Castle Biosciences provides test solutions for the diagnosis and treatment of dermatologic cancers. Previously, Miles co-founded and led Novaestiq Corp., building a novel aesthetics platform, raising multi-millions in early financing, and securing strategic distribution with Croma Pharma in North America. He successfully positioned Novaestiq for a significant strategic exit in 2025.

Before Novaestiq, Miles was President & General Manager, North America at Galderma, leading three business units—Aesthetics, Consumer, and Prescription—across North America, with an expansive employee base and over $1.2B in revenue. He drove sustained growth and margin expansion, and scaled several iconic consumer, aesthetic and prescription brands including Cetaphil®, Differin®, Dysport®, Sculptra®, Restylane® and Epiduo®. Miles was part of the executive leadership team that supported EQT’s multi billion dollar acquisition of Galderma in late 2019.

Earlier, at Nestlé Skin Health, he built the U.S. Consumer Business Unit from the ground up, delivering double-digit organic growth and leading the first FDA-approved RX-to-OTC acne switch in 30 years (Differin® Gel).

Miles seeks to bring a blend of boardroom discipline and entrepreneurial drive to his next role as CEO of Conexeu™ Sciences Inc. Known for building high-performing teams and shaping cultures that thrive under change, he combines governance depth, capital strategy expertise, and hands-on operating leadership. At Conexeu™, he will lead the charge to bring first-in-class disruptive human collagen technologies to market across aesthetics, wound care, and regenerative medicine—pioneering a category that sits at the intersection of science, patient impact, and long-term value creation.

Mr. Inouye was appointed as the Chief Financial Officer for Conexeu Sciences in November 2023. Later, in April 2025, he was also appointed to the positions of Secretary and Treasurer to the Company’s board of directors. A seasoned financial executive of nearly 40 years, Steve’s career focus has naturally been upon accounting and tax management. However, he also provided strategic guidance to an array of both private and publicly held companies, where he served in pivotal senior leadership roles.

Spanning startup and small-cap public market sectors, Mr. Inouye holds a strong command of capital market advisory services. Therein, his expertise includes guidance for ‘go-public’ transactions where he has contributed to effective capital raising initiatives, which have fueled corporate growth. Steve’s veteran experience also encompasses both US- and Canadian-listed companies, guiding in their adherence to prevailing securities regulations and corporate governance. Although a generalist, Mr. Inouye’s greater focus has been devoted to companies operating in the biopharmaceutical, natural healing, and fitness industries.

With over 25 years in dermatology and aesthetics, Brian has served as CMO of Suneva Medical (acquired by Tiger Bio, 2024) and VP of Medical Affairs for Merz North America, leading the launch of Radiesse. As former Asst. Professor at UT Southwestern, focusing on cellular and molecular wound repair mechanisms. Led medical affairs teams and 40+ educators to ensure optimal clinical outcomes, patient safety, and successful product life cycles in aesthetic medicine. Spearheaded scientific and clinical initiatives to enhance regenerative aesthetic technologies, ensuring safe, effective treatments and advancing industry standards.

Dr. Claudia Chavez-Munoz is a distinguished surgeon-scientist recognized internationally for her pioneering contributions to burn care, wound healing, and tissue regeneration. She is the founder of Conexeu Science Inc., established in 2023. Initially appointed as the company’s Chief Medical Officer (October 16, 2023 – April 8, 2025), she now serves as Chief Science Officer, leading innovation in regenerative therapeutics.

Currently, Dr. Chavez-Munoz serves as an Adjunct Professor in the Faculty of Medicine at the University of British Columbia, where she has mentored graduate trainees (2 MSc, 2 PhD) and contributes to the Undergraduate MD Program through lectures in regenerative biology and surgical innovation. Her academic research continues to focus on extracellular matrix (ECM)-based therapies and 3D organ reseeding. At Conexeu, she leads the scientific direction of the 10 Minute Tissue™ scaffold platform, translating more than a decade of high-impact research into next-generation, clinically actionable solutions for complex wound healing, reconstructive surgery, and regenerative medicine.